Beyond SSRIs: Understanding Rapid-Acting Antidepressants—from rTMS to Ketamine and Psychedelics

Depression treatment is shifting toward rapid-acting interventions that achieve results in hours to days. This session provides an overview of rTMS, ketamine and esketamine, and emerging psychedelic therapies such as psilocybin and MDMA. Attendees will learn the mechanisms of action, metabolism, and safety profiles of these treatments, along with potential drug–drug interactions and practical guidance for clinical use. Emphasis will be placed on translating neurobiologic insights into safe, effective patient care, empowering clinicians to navigate this expanding therapeutic landscape with confidence and precision.